so A0 120 Rev, 3/04
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`PO. Box 1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`
`TRADEMARK
`
`Alexandria, VA 22313-1450
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § l 116 you are hereby advised that a court action has been
`filed in the US. District Court
`Southern District of New York
`on the following
`X Patents or
`Trademark53
`
`DOCKET NO.
`
`DATE FILED
`
`US. DISTRICT COURT
`
`1:10-CV—6463
`PLAINTIFF
`
`8/30/2010
`
`Southern District ofNew York
`
`DEFENDANT
`
`Pfizer. Inc., et al
` Mylan Inc., et al
`
`
`
`
`
`PATENT OR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`7, at; we
`
`
`
`
`
`HOLDER OF PATENT OR TRADEMARK
`
`See Attached List
`
`
`
`
`
`
`
`DATE INCLUDED
`
`In the above—entitled case, the following patent(s)/ trademark(s) have been included:
`INCLUDED BY
`
`PATENT OR
`TRADEMARK NO.
`
`I:l Amendment
`DATE OF PATEN T
`OR TRADEMARK
`
`E] Answer
`
`I:I Cross Bill
`
`El Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`In the above—wentitled ease, the following decision has been rendered orjudgement issued:
`DECISION/JUDGEMENT
`Attached: COPY OF NOTICE OF DISMISSAL.
`
`Ruby Krajick
`
`' UTY CLERK
`
`'
`
`,
`
`Copy l—Upon initiation of action, mail this copy to
`Copy 2mUpon filing document adding patent(s), m:
`
`Copy 3—. pon termination of action, mail this copy to Director
`copy to Director Copy 4—Case file copy
`
`
`
`12/22/2010
`
`
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE SOUTHERN DISTRICT OF NEW YORK
`
`
`PFIZER INC, PFIZER PRODUCTS INC,
`and (1P. PII/\RMAC1£U"l"i('I/\l,S
`
`lN‘E'l-ZRNA'I‘IONAL (I‘.V.,
`
`Plaintiff‘s,
`
`MYIAN INC. and
`
`MYLAN I’I’IARMACHU'I'ICALS INC,
`
`Defendants.
`
`'vvvvvvvvvwvvvvv‘vv
`
`Civil Action No. 10-6463
`
`Judge William H. l’auley
`
`PFIZER INC., PFIZER PRODUCTS INC, AND C.P. PHARMACEUTICALS
`INTERNATIONAL C.V.’S NOTICE OF DISMISSAL WITHOUT PREJUDICE
`
`PLlEASl'i TAKIB NO'l'ICI't‘ that, pursuant to lied. R. Civ. P. 41(a)(1)('/\)(i), Plaintiffs
`
`Pl’izer lne., Piizer Products Inc., and UP. Pharmaceuticals International CV. (collectively,
`
`"Pfizer’j hereby voluntarily dismiss this action without prejudice as to Defendants Mylan Inc.
`
`and Mylan Pharmaceuticals Inc. (collectively, “Mylan”). Mylan has not filed a responsive
`
`pleading to Pfizer’s Complaint.
`
`Dated: December 21, 2010
`
`Respectfully submitted,
`
`
`
`.
`
`)rivas (DD 889!)
`
`.iel'l'rey .i. Oelke (JO 2534)
`Adam Galitan (AG 8802)
`Brendan G. Woodard (BW 6194)
`
`
`
`R. Gregory Parker (RP 2121)
`WHITE & CASE LLP
`
`1 155 Avenue of the Americas
`
`New York, New York 10036
`
`/1(lw-‘ney.sjfi)r Plainu'flS Rffzer 1mm,
`Bfizer Products' Inc. and
`(,'.1’. Pharmaceutical? International (.'. V.
`
`
`
`
`
`Case 1:10—cv—06463-WHP Document 1-1
`
`Filed 08/30/10 Page 2 of 39
`
`||||||1||1||ll|||||11|||11|||11111111111111
`
`USU/072651 19132
`
`(12) United States Patent
`US 7,265,119 BZ
`(10) Patent No.:
`Sep. 4, 2007
`(as) Date 01' Patent:
`Bogle et a].
`
`(54) TARTRATE SALTS 0F
`5,8,14-TRIAZATETRACYCLOH0.3.1.0“‘.0”]-
`HEXADECA-2(11),3,5,7,9-PENTAENE AND
`PHARMACEUTICAL COMPOSITIONS
`THEREOF
`
`(75)
`
`inventors: David E. Bugle, Jewett City, CT (US);
`Glenn R. WilliamS. Oaksville (CA);
`Peter R. Rose, Ledyard, CT (US)
`
`(73) Assignce: Pfizer Inc, New York, NY (US)
`
`FOREIGN PATENT DOCUMENTS
`
`EP
`W0
`
`1078637
`W0 9935131
`
`2/2001
`7/1999
`
`OTHER PUBLICATIONS
`
`Paul H. Mezzochi, el al.. “Synthesis and Pharmacological Activity
`of 2.3.4.5-Tetrahydxo—1.S-Methano-lH-S-Benzazepincs", J, Med.
`Chem, vol. 22. No. 4, [979, pp. 455-457. XP002090422.
`
`( * ) Notice:
`
`Subject to any disclaimer, the term of this
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 105 days.
`
`Primary ExaminerwBruck Kille
`(74) Attorney, Agent, or Firm—Steve T. Zelson; A. David
`Joran
`
`(2)) App]. No.1 11/069,724
`
`(22)
`
`Filed:
`
`Feb. 28, 2005
`
`(65)
`
`Prior Publication Data
`US 2005/0148591 Al
`Jul. 7, 2005
`
`(57)
`
`ABSTRACT
`
`invention is directed to the taro-ate salts of
`The present
`5,8, l 4-triazatetracyclo[10.3.l.02'“ .04’9]-hexadeca—2(l I ),3,
`5,7,9-petttaene:
`
`Related US. Application Data
`(63) Continuation of application No. 10/139,730, filed on
`May 6. 2002, now Pat. No. 6,890,927.
`
`(60) Provisional application No. 60/290,861, filed on May
`14, 2001.
`
`ijm
`
`Int. (:1.
`com 241/36
`A61K 31/50
`A61K 31/495
`(52) U.S.Cl.
`(58) Field of Classification Search
`
`(51)
`
`(55)
`
`(2006.01)
`(2006.01)
`(2006.01)
`
`5141250;5441343
`544/343;
`514/250
`See application file for complete search history.
`References Cited
`U .S. PATENT DOCUNUENTS
`
`and pharmaceutical compositions thereof. The present
`invention in particular is directed to the L-tartmte salt, and
`further to the various poiymorphs of the L—tartrate salt,
`including two distinct anhydrous polymorphs (referred to
`herein as Forms A and B) and a hydrate polymorph (referred
`to herein as Form C). in addition, the present invention is
`also directed to the D-tartrate salt of 5,8,14-ti-iazatetracyclo
`[10.3.1.02‘”.04’91-hexadeca-ZUl),3,5,7,9-pentaene and the
`various polymorphs thereof; as Well as the D,L-tartrate salt
`thereof and its polymorphs, and the meso-tartrate salt thereof
`and its polymorphs.
`
`3.471.503 A
`
`10/1969 Carson
`
`15 Claims, 20 Drawing Sheets
`
`
